

# Travel Immunizations in Patients on Biologics

*Live vaccinations could potentially reactivate in the setting of a suppressed immune system.*

BY RICHARD HYER

FROM A SYMPOSIUM SPONSORED BY THE ACR

CHICAGO — The patient on biologic therapy who must travel and requires immunization with a live attenuated virus or bacteria should be immunized before beginning biologic therapy, according to a case report presented to a symposium that was sponsored by the American College of Rheumatology.

“Think hard about the patient’s life before you put them on biologic therapy, and immunize before you give the medications,” advised Dr. Clifton O. Bingham, who is director of the rheumatology clinics at Johns Hopkins University, Baltimore. However, he acknowl-

**The immunomodulators etanercept and methotrexate could be withheld for at least a period of 1 month prior to administering yellow fever vaccine.**

edged that this would not always be possible.

The case was a 35-year-old woman with psoriatic arthritis whose work required her to travel to Burkina Faso, a small, landlocked country in West Africa, where yellow fever is endemic. The patient’s skin and articular disease was well controlled with etanercept and methotrexate.

As a practical matter, Dr. Bingham said that the immunomodulators etanercept and methotrexate could be withheld for at least a period of 1 month, and then the patient could be administered yellow fever vaccine. He advised waiting 2-3 weeks before restarting the medication.

“The disease may flare during that period of time, so that’s the risk you take,” he said.

If the patient was required to travel to the infected area with only 2 weeks’ notice, Dr. Bingham advised providing a letter of medical contraindication to yellow fever vaccination.

“That should allow her to enter the

country, but you tell her to be really careful.” When a patient is on biological therapy, he said it is important to understand which live vaccinations could potentially reactivate in the setting of immunosuppression.

Vaccines that contain live attenuated

viruses or bacteria include varicella; intranasal influenza/H1N1; measles, mumps, and rubella; yellow fever; oral polio; oral typhoid; vaccinia (smallpox); BCG; and rotavirus.

Disseminated disease has been reported in immunocompromised patients who were immunized with live-virus vaccines. Live viral dissemination has occurred in patients during chemotherapy, and there have been cases of infec-

tion in patients receiving immunosuppression for organ transplantation. Live virus dissemination has also been reported in patients with HIV infection. (J. Infect. Dis. 2008;197 [Suppl 2]; Clin. Infect. Dis. 2009;49:1550-6; AIDS Rev. 2007;9:173-87). “So, the recommendation is, with people who are on biologics and people who are immunosuppressed, they should not receive these live vaccinations,” Dr. Bingham said.

For postmenopausal women with osteoporosis at high risk for fracture

## ON THE VERGE OF ANOTHER FRACTURE



### FORTEO® (TERIPARATIDE [rDNA ORIGIN] INJECTION) SELECT SAFETY INFORMATION:

Prescribe FORTEO only for patients for whom the potential benefits are considered to outweigh the potential risks. FORTEO should not be prescribed for patients at increased baseline risk for osteosarcoma, including those with Paget’s disease of bone, unexplained elevations of alkaline phosphatase, pediatric and young adult patients with open epiphyses, or prior external beam or implant radiation therapy. Additionally, patients with bone metastases or a history of skeletal malignancies, metabolic bone diseases other than osteoporosis, or pre-existing hypercalcemia should not receive FORTEO.

Use of FORTEO for more than 2 years during a patient’s lifetime is not recommended.

Please see Important Safety Information and Brief Summary of Prescribing Information on adjacent pages.

Rheumatology News

THE LEADER  
IN NEWS  
AND  
MEETING  
COVERAGE

#1

is the best-read  
publication among  
office- and hospital-  
based rheumatologists.

Source: Kantar Media, Focus® Medical/Surgical  
December 2009 Readership Summary;  
Rheumatology Office & Hospital, Table 143  
Projected Average Issue Readers

Up-to-date vaccine information is available online from the Centers for Disease Control and Prevention ([www.cdc.gov/vaccines/pubs/vis/default.htm](http://www.cdc.gov/vaccines/pubs/vis/default.htm)).

An audience member asked, "Do you think that in some cases it may be a better choice to subject somebody to the risk of an attenuated organism, as opposed to the risk of wild-type disease in an area where the disease may be highly endemic?"

Dr. Bingham said, "The risk of developing yellow fever is about 50 per 100,000 in western Africa, and about 10

per 100,000 in Central and South America. So it is a low risk.

"But if you delve a little deeper into that information, you find out that many of those patients die. It's potentially a fatal disease. So you do have to balance the risk." ■

**Disclosures:** Dr. Bingham disclosed financial relationships with Abbott, Amgen, Bristol-Myers Squibb, Centocor, Cypress Bioscience, Genentech, Merck, Novartis, Osiris Therapeutics, Procter & Gamble, Roche, Sonosite, Targeted Genetics, UCB, and Wyeth.

**VERBATIM**

*'[A]ll the orthopedic surgeons I know refuse to do the surgery for very obese patients. In my practice, such patients often choose bariatric surgery rather than dieting before they have their knees replaced.'*

Dr. Larry Greenbaum on how uncommon it is for very obese patients with knee OA to lose weight through diet and exercise, page 61

# NOW IS THE TIME FOR ANABOLIC ACTION



**FORTEO IS INDICATED:**

- For the treatment of postmenopausal women with osteoporosis at high risk for fracture

**WARNING: POTENTIAL RISK OF OSTEOSARCOMA**

In male and female rats, teriparatide caused an increase in the incidence of osteosarcoma (a malignant bone tumor) that was dependent on dose and treatment duration. The effect was observed at systemic exposures to teriparatide ranging from 3 to 60 times the exposure in humans given a 20-mcg dose. Because of the uncertain relevance of the rat osteosarcoma finding to humans, prescribe FORTEO® (teriparatide [rDNA origin] injection) only for patients for whom the potential benefits are considered to outweigh the potential risk. FORTEO should not be prescribed for patients who are at increased baseline risk for osteosarcoma (including those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, pediatric and young adult patients with open epiphyses, or prior external beam or implant radiation therapy involving the skeleton).

  
**FORTEO™**  
 teriparatide (rDNA origin) injection  
 ANABOLIC ACTION FOR NEW BONE

